The corporate-backed genetic testing service is joining forces with an NYSE-listed special purpose acquisition company sponsored by Virgin Group.

23andMe, the US-based genetic testing service backed by corporates Alphabet, WuXi AppTec, Johnson & Johnson, GlaxoSmithKline (GSK), Roche and Illumina, agreed a reverse merger with a special purpose acquisition company (SPAC) yesterday. VG Acquisition Corp, which is sponsored by conglomerate Virgin Group, floated on the New York Stock Exchange in a $480m initial public offering…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.